1st Department of Medicine, Semmelweis University, Budapest, Hungary.
Am J Gastroenterol. 2012 Apr;107(4):579-88. doi: 10.1038/ajg.2011.448. Epub 2012 Jan 10.
Medical therapy for Crohn's disease (CD) has changed significantly over the past 20 years with increasing use of immunosuppressives. In contrast, surgery rates are still high and there is little evidence that disease outcomes for CD have changed over the past decades. The objective of this study was to analyze the evolution of the surgical rates and medical therapy in the population-based Veszprem province database.
Data of 506 incident CD patients were analyzed (age at diagnosis: 31.5 years, s.d. 13.8 years). Both hospital and outpatient records were collected and comprehensively reviewed. The study population was divided into three groups by the year of diagnosis (cohort A: 1977-1989, cohort B: 1990-1998 and cohort C: 1999-2008).
Overall, azathioprine (AZA), systemic steroid, and biological (only available after 1998) exposure was 45.8, 68.6, and 9.5%, respectively. The 1- and 5-year probability of AZA use were 3.2 and 6.2% in cohort A, 11.4 and 29.9% in cohort B, and 34.8 and 46.2% in cohort C. In a multivariate Cox-regression analysis, decade of diagnosis (P < 0.001, hazard ratio (HR)(cohorts B-C): 2.88-6.53), age at onset (P = 0.008, HR: 1.76), disease behavior at diagnosis (P < 0.001, HR(complicated): 1.76-2.07), and need for systemic steroids (P < 0.001, HR: 2.71) were significantly associated with the time to initiation of AZA therapy. Early AZA use was significantly associated with the time to intestinal surgery in CD patients; in a multivariate Cox analysis (HR: 0.43, 95% confidence interval (CI): 0.28-0.65) and after matching on propensity scores for AZA use (HR: 0.42, 95% CI: 0.26-0.67).
This population-based inception cohort has shown that the recent reduction in surgical rates was independently associated with increased and earlier AZA use.
过去 20 年来,随着免疫抑制剂的广泛应用,克罗恩病(CD)的医学治疗发生了重大变化。相比之下,手术率仍然很高,而且几乎没有证据表明 CD 的疾病结局在过去几十年中发生了变化。本研究的目的是分析基于人群的韦斯普雷姆省数据库中手术率和医学治疗的演变。
分析了 506 例新发 CD 患者的数据(诊断时年龄:31.5 岁,标准差 13.8 岁)。收集并全面审查了住院和门诊记录。研究人群按诊断年份分为三组(队列 A:1977-1989 年;队列 B:1990-1998 年;队列 C:1999-2008 年)。
总体而言,硫唑嘌呤(AZA)、全身类固醇和生物制剂(仅在 1998 年后可用)的暴露率分别为 45.8%、68.6%和 9.5%。在队列 A 中,AZA 使用的 1 年和 5 年概率分别为 3.2%和 6.2%,在队列 B 中为 11.4%和 29.9%,在队列 C 中为 34.8%和 46.2%。在多变量 Cox 回归分析中,诊断十年(P < 0.001,风险比(HR)(队列 B-C):2.88-6.53)、发病年龄(P = 0.008,HR:1.76)、诊断时疾病行为(P < 0.001,HR(复杂):1.76-2.07)和需要全身类固醇(P < 0.001,HR:2.71)与 AZA 治疗开始时间显著相关。早期 AZA 使用与 CD 患者的肠道手术时间显著相关;在多变量 Cox 分析(HR:0.43,95%置信区间(CI):0.28-0.65)和在 AZA 使用倾向评分匹配后(HR:0.42,95%CI:0.26-0.67)。
本基于人群的发病队列研究表明,近期手术率的下降与 AZA 使用的增加和提前使用独立相关。